The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 1 CME credit.
Read More
This 2019 randomized, double-blind, placebo- controlled trial study casts doubt on using gabapentin enacarbil extended-release (GE-XR) (Horizant), an extended-release version of gabapentin, for treatment in patients with alcohol use disorder
Read More
This 2019 retrospective study examines the potential benefits of using buprenorphine/naloxone to treat co-occurring PTSD and opioid use disorder.
Read More
This News of Note discusses the first FDA-approved mobile app for SUDs, called reSET-O. Classified as a mobile medical app (MMAs), reSET-O can be used as an adjunct to outpatient opioid use disorder treatment. Unlike most apps, reSET-O requires a prescription to unlock and use.
Read More
Naloxone, a rescue medication effective for reversing opioid overdose, will soon be available in two generic forms for layperson use. This news of note summarizes these generic, lower-cost products.
Read More
Addiction treatment during incarceration is limited, and release from incarceration presents its own set of challenges. In this QA interview, Dr. Karen Cropsey discusses effective treatment options for patients with substance use disorders transitioning to or from incarceration.
Read More
Addiction is stigmatized, resulting in historically strict confidentiality rules. But how do we interpret HIPAA and other regulations in 2019 addiction practice? Do we need a ROI every time we communicate with other clinicians/institutions, which seems cumbersome and counterproductive? In this article we cover what you need to know about confidentiality in addiction treatment.
Read More
Dr. Capurso is an assistant professor of psychiatry and Director of Didactic Education at the Yale University School of Medicine. He practices clinically at the West Haven Veterans Administration Hospital. He attended medical school at Yale, where he received his MD, and where he conducted research in the Department of Biomedical Engineering. He stayed at Yale for residency and addiction psychiatry fellowship training. As a clinician, Dr. Capurso is the medical director of the VA’s Detoxification & Addiction Stabilization Service and the Psychosocial Residential Rehabilitation Program.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
